Journal article
The economic value of a visceral leishmaniasis vaccine in Bihar state, India
Visceral leishmaniasis (VL) is responsible for substantial morbidity and mortality and current available treatments have many limitations. The ability of VL infection to generate life-long immunity offers promise for the development of a VL vaccine. A VL vaccine candidate has recently completed phase I clinical trials. We constructed a computer simulation model to determine the potential economic value of a VL vaccine in the endemic region of Bihar state, India. Results found a potential vaccine to be cost-effective (and in many cases economically dominant, i.e., saving costs and providing health benefits) throughout a wide range of vaccination costs and vaccine efficacies, and VL risks. Overall, our study strongly supports the continued development of a VL vaccine.
Authors
Languages
- English
Publication year
2012
Journal
Am J Trop Med Hyg
Volume
3
Type
Journal article
Categories
- Vaccines & delivery devices
Countries
- India
Tags
- New vaccine introduction
WHO Regions
- South-East Asia Region